Development of a Generic Pharmaceutical Solid Dosage Form Using Quality by Design (QbD)
Resumen
The Pharmaceutical Generic Sector
has been growing over the past years and it is
expected to surpass brand drugs in sale over next
years. The FDA now recommends Quality by
Design to develop Generic Drugs. The present
work was aim to develop a Generic Version of
Polytripcin Immediate Release Tablet (Polytripsin
is a given name to protect the identity of the real
product) using Quality By Design, equivalent to the
Reference Listed Drug (RLD) Brand Polytripcin
600 mg. The physical properties (Flow and Particle
Size Distribution) of the Active Substance were
evaluated. Two Formulations were proposed based
on the physical characteristic of the Active Drug.
The formulations were evaluated for blend and
tablet physical characterization. Formulation # 2
had a Dissolution Profile Similarity Factor (F2) of
65, indicating similarity to the RLD. A Design of
Experiments (DOE) for Process Improvement was
also performed to correct flow problems during
compression of the blends.
Key Terms - Design of Experiment, Generic
Drug Pharmaceutical Development, Quality by
Design, Reference Listed Drug.